MphasiS, WordDoc partner to create self-service solution for health plans, members
PHOENIX MphasiS Healthcare Solutions and WorldDoc have entered into a partnership, under which WorldDoc will integrate its online health assessment and preventive tools with MphasiS’ online self-service solution. This will allow both companies to offer a more complete solution to health plans, third party administrators and employers.
Under the deal, WorldDoc will use MphasiS’ WEBeci solution to streamline access toward its health management system to allow users to have access to more information and tools with a single user ID and password. WEBeci offers automation communication between a health plan and users and will help WorldDoc users reduce their costs and improve their operations. WEBeci, for example, allows providers and plan members to check claim status; verify insurance eligibility; print benefit plan documentation; search for and view provider information; and perform various enrollment functions over a dedicated, secure, private-labeled website.
The partnership with WorldDoc offers WEBeci clients access to a wide range of decision support tools, allowing users to assess health risks; evaluate symptoms to learn when self-care options are safe and when they should seek immediate medical attention; compare prescription prices and find generic alternatives to medications; maintain online personal health records; research conditions and treatments in an extensive online library written by physicians.
“The partnership with MHS helps consumers bridge the information silos between claims systems, benefit plans, personal health records and medications,” according to Rahul Singal, president and chief executive officer of WorldDoc. “MHS’ leading-edge technology platform greatly increases the value of our products and the experience of members to our joint customers.”
Study shows positive results from adding Lipitor early to blood pressure treatment
NEW YORK According to a new study, when Lipitor was added as an early treatment to lower blood pressure, the drug showed a 36 percent reduction in the risk of fatal or non-fatal heart attacks over five years.
The study, entitled Anglo-Scandinavian Cardiac Outcomes Trial, was conducted over a five-year period in Europe with over 19,000 patients, with the first three years being dedicated to comparing Lipitor, a Pfizer product, with a placebo. The additional two years were used for post-study follow up. At the start of the study, patients had high blood pressure and additional cardiovascular risk factors but no coronary heart disease.
“This study highlights the importance of initiating medical treatment for both blood pressure and cholesterol as soon as possible, and raises questions about medical guidelines that do not focus on early intensive treatment of multiple risk factors, notably blood pressure and cholesterol, in patients with moderate cardiac risk,” according to Bryan Williams, chairman of the British Hypertension Society Guideline working party and professor of medicine, University Hospitals NHS Trust, Leicester, United Kingdom.
Patients in ASCOT-LLA had normal to mildly elevated cholesterol levels, were not candidates for lipid-lowering treatment at the time of the study initiation, and received Lipitor 10 mg or a placebo at the outset of the trial.
At the end of the follow-up period, LDL-C or bad cholesterol levels were similar in both groups as a result of Lipitor treatment and the average blood pressure level was significantly reduced from 164/95 mmHg to 137/78 mmHg with the blood pressure lowering therapy.
Taro submits Flo-Pred application to FDA in new PLR format
WASHINGTON Taro Pharmaceuticals applied Thursday to the Food and Drug Administration seeking approval for its new oral solution, Flo-Pred.
Flo-Pred (prednisolone acetate oral suspension) is an anti-inflammatory or immunosuppressive agent indicated for a variety of diseases and conditions, including allergic, dermatologic, gastrointestinal and hematologic.
The medication also enjoys the distinction of—pending approval—being the first oral steroid label in the FDA’s new physician labeling rule format. The PLR format, which went into effect June 19, requires new content, new structure and new highlights information, as compared to the former structured product labeling.